Know Your Competitors
This drug went from being one of our competitors to one of our most exciting NS assets
Caplyta
This blockbuster drug was a throw-in during Merck's acquisition of Organon/Schering-Plough and its development was almost terminated
Keytruda
This bladder cancer drug is inspired by the James Bond franchise and could be a stiff competitor to TAR-200
CG0070 (trial name - BOND-003)
This January conference is a major venue for M&A activity across biotech/pharma
JP Morgan
This BMS drug could be our biggest competitor to icotrokinra in immunology oral market
Sotyktu
The two drugs starring in Nathan Vardi's book, "For Blood and Money" detailing a biotech showdown
Imbruvica and Calquence
This argenx drug is going to be a strong threat to our exciting launch of Imaavy in the gMG space
Vyvgart
This lab developed two drugs (among others) that are major highlights of our current portfolio
Langer lab (nipo and TAR-200)